Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”

Reducing Dscam1 diversity decreases adult lifespan in a cluster-specific manner, also see S6 and S7 Figs. by Haiyang Dong (4783608)

Questionnaire description. by Cristobal Padilla-Fortunatti (21376807)

“…<div><p>Background</p><p>During the last decades, intensive care unit (ICU) mortality rates have significantly decreased but this progress has come with unintended consequences for patients and their caregivers. …”

Ischemic heart disease-related mortality trends in older adult population and stratified for census regions in 1999–2020. by Fakhar Latif (19760906)

Subjects:

Cases and age-standardized rates of hematological malignancies in mainland China and their temporal trends. by Yu Fu (16582)

Subjects:

Projections of incidence for hematological malignancies in mainland China. by Yu Fu (16582)

Subjects:

Ischemic heart disease-related mortality trends in older adult population and stratified for metropolitan vs. non-metropolitan in 1999–2020. by Fakhar Latif (19760906)

Subjects:

Age- and sex-specific distribution of prevalence, incidence, mortality, and DALY rates for lymphoma, multiple myeloma, and other hematological neoplasms in mainland China. by Yu Fu (16582)

Subjects:

Disease burden trends of leukemia and lymphoma analyzed by joinpoint regression analysis in mainland China. by Yu Fu (16582)

Subjects:

Ischemic heart disease-related mortality trends in older adult population and stratified for gender in 1999–2020. by Fakhar Latif (19760906)

Subjects:

Disease burden trends of multiple myeloma and other hematological neoplasms analyzed by joinpoint regression analysis in mainland China. by Yu Fu (16582)

Subjects:

Ischemic heart disease-related mortality trends in older adult population and stratified for older vs. young population in 1999–2020. by Fakhar Latif (19760906)

Subjects:

Cases and age-standardized rates of hematological malignancies in Taiwan and their temporal trends. by Yu Fu (16582)

Subjects:

The raw data used in this study. by Yu Fu (16582)

Subjects:

Deaths, overall AAMRs, and Annual Percent Change (APC) of ischemic heart diseases-related mortality in older adults in the United States, 1999 to 2020. by Fakhar Latif (19760906)

Subjects:

Ischemic heart disease-related mortality trends in older adult population and stratified for causes in 1999–2020. by Fakhar Latif (19760906)

Subjects:

Age- and sex-specific distribution of prevalence, incidence, mortality, and DALY rates for leukemia in mainland China. by Yu Fu (16582)

Subjects:

Ischemic heart disease-related mortality trends in older adult population and stratified for age groups in 1999–2020. by Fakhar Latif (19760906)

Subjects: